<DOC>
	<DOCNO>NCT02069886</DOCNO>
	<brief_summary>The CENTAurus trial prospective clinical study design address systematically relevant endocrine complication iron overload thalassemic population , primary objective assessment effect deferasirox therapy glucose metabolism/homeostasis . Other endocrine parameter complementary supportive primary objective assess analyze study . A number lab parameter related ax endocrine system collect analyzed .</brief_summary>
	<brief_title>Effect Deferasirox Endocrine Complications Subjects With Transfusion Dependent Thalassemia</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>1 . Beta thalassemia major severe intermedia patient transfusion dependent transfusional iron overload 2 . Patients diagnosis impair fast glucose impair glucose tolerance 4.Patients na√Øve deferasirox patient already receive deferasirox suboptimal dos 5.Cardiac MRI T2* &gt; 10 msec ; 7.normal cardiac function ( LVEF &gt; 56 % ) ; 1 . Non transfusional hemosiderosis ; 2 . Patients diabetes mellitus ( genetic secondary ) history diabetes mellitus 1st degree relative ; 4.Patients receive organ transplant ; 5.Patients galactose intolerance , severe lactase deficiency glucosegalactose malabsorption ; 6.Patients unable tolerate ( unacceptable toxicity ) prior treatment deferasirox ; 7.History hypersensitivity study drug excipients ; 8 . Renal impairment 10 . Liver impairment ; 11.Patients active chronic hepatitis B infection , active hepatitis C infection ; Other protocoldefined inclusion/exclusion criterion may apply '' end</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Endocrine complication</keyword>
	<keyword>transfusion dependent thalassemia</keyword>
</DOC>